Molecular Optimization Via Exercise (MOVE)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

80 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-09-19

Study Completion Date

2027-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study is to investigate characteristics of muscle, blood, and urine samples from older adults (ages 65-80) who are either sedentary or athletes performing at an elite level for their age. This observational study will include bio-specimen collection, as well as physical and cognitive function testing and body composition.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Healthy Aging Through Optimized Exercise

NCT07093216

Aging

NOT_YET_RECRUITING NA

The Effect of Exercise on Myokine Production in Aging Persons

NCT05571709

Aging Exercise

UNKNOWN NA

Mechanisms of Anabolic Resistance in Older Humans

NCT06617195

Aging

RECRUITING

The Effects of Exercise Intervention on Skeletal Muscle and Other Organs in Aged Population and the Discovery of Associated Circulating Biomarkers

NCT06660706

Age-related Functional Decline

RECRUITING NA

Fitness, Cellular Aging, and Caregiver Stress Study

NCT01993082

Aging Stress Disease Risk

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study will enroll a total of 80 subjects-20 of each gender for each cohort. Participation in the study involves 3 visits that must take place within 12 weeks. Optional l follow up visits may be completed at 12- and 24- months after completion of the main study.

The first visit is a screening and enrollment visit. At this visit, informed consent will be obtained and a detailed medical history, screening blood sample collected, and physical assessment will be performed (including, but not limited to vital signs, resting ECG, body composition). Additionally, an exercise history interview will be performed to assess for cohort eligibility. Participants will be familiarized with testing equipment during the screening visit and will perform the Astrand-Rhyming submaximal bicycle test. A short physical function testing battery will be performed, including the short physical performance battery, 6 minute walk test, grip strength, 1 rep max leg press, and leg press fatigue testing.

The second visit will include maximal exercise testing, quality of life assessment, and cognitive function testing. Participants will be allocated into their cohort at this visit.

The third visit will include thigh muscle sample collection via needle biopsy and blood sample collection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aging

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Group 1 cohort: Healthy Older Adults (HOA)

This cohort will include healthy older adults, aged 65y or over, who participate in less than 60 minutes of structured exercise each week.

Observational

Intervention Type OTHER

No intervention

Group 2 cohort: Elite Older Athletes (EOA)

This cohort will include healthy older adults, aged 65y or over, who are elite athletes for their age (determined by interview and VO2max)

Observational

Intervention Type OTHER

No intervention

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Observational

No intervention

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Exclusion Criteria

1. Subject requires assistance with any activity of daily living, excluding continence.
2. Subject lives in an institutional setting (skilled nursing facility or residential care facility for the elderly).
3. Abnormal bleeding or coagulopathy (self-report): History of a bleeding disorder, wound healing disorder or clotting abnormality.
4. Female participants must be post-menopause.
5. Musculoskeletal conditions that would prevent completion of any required exercise testing.
6. Elevated blood pressure readings (screening test): Resting Systolic Blood Pressure (SBP) ≥150 mmHg or resting Diastolic Blood Pressure (DBP) ≥90 mmHg
7. Diabetes (self-report and screening tests): Treatment with any hypoglycemic agents (self-report), fasting glucose \>125 mg/dL (screening test; may reassess once), use of hypoglycemic drugs for non-diabetic reasons (self-report).
8. Pulmonary (self-report): Clinical diagnosis of any chronic pulmonary disease that limits exercise capacity.
9. Cardiovascular (self-report, screening test, and clinician judgement): Congestive heart failure, coronary artery disease, significant valvular disease, congenital heart disease, serious arrhythmia, pulmonary embolism, stroke, or symptomatic peripheral artery disease (self-report, screening test). Specific criteria used to determine whether a volunteer can undergo the screening CPET follow the American Heart Association (AHA) Criteria \[6\]. Inability to complete the CPET. Reassessment of the CPET may be allowed under some circumstances (e.g., test was not a maximal effort)
10. Abnormal blood lipid profile (screening test): Fasting triglycerides \>500 mg/dL. Low-density lipoprotein cholesterol (LDL-C) \>190 mg/dL
11. Cancer (self-report): History of cancer treatment (other than non-melanoma skin cancer, or chronic lymphocytic leukemia) and not "cancer-free "for at least 2 years. Anti-hormonal therapy (e.g., for breast or prostate cancer) within the last 6 months.
12. Chronic active or latent infection (self-report): Active or latent infections requiring chronic antibiotic or anti-viral treatment, excluding herpes simplex virus. Chronic active infection whether on chronic antimicrobials or not. Human Immunodeficiency Virus. Active hepatitis B or C undergoing antiviral therapy. Individuals successfully treated for hepatitis C and virologically negative for at least 6 months are not excluded.
13. Liver enzyme tests (alanine transaminase, aspartate transaminase) (screening test): \>2 times the laboratory upper limit of normal. Reassessment during screening may be allowed under some conditions (e.g., recent use of acetaminophen). Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting.
14. Chronic renal insufficiency (screening test): Estimated glomerular filtration rate \<60 mL/min/1.73 m2 from serum creatinine (mg/dL) by the Chronic Kidney Disease Epidemiology Collaboration equation. Subjects must be able to produce urine. Reassessment may be allowed under some conditions (e.g., questionable hydration status or other acute renal insult)
15. Hematocrit (screening test): Hematocrit \>3 points outside of the local normal laboratory ranges for women and men. Reassessment may be allowed under certain conditions. Individuals may be referred to their PCP for evaluation; any medication change must be stable for ≥3 months prior to retesting.
16. Blood donation (self-report): Whole blood donation in the last 3 months or plans for blood donation during the entire protocol period. Platelet or plasma donation in the last week or plans for platelet or plasma donation during the entire protocol period.
17. Autoimmune disorders (self-report): Individuals receiving any active systemic treatment (including immunosuppressants and/or monoclonal antibodies) within the last 6 months.
18. Alcohol consumption (self-report): Current consumption of more than 7 drinks per week for women More than 14 drinks per week for men. History of binge drinking in the past five years (≥5 drinks for males or ≥4 drinks for females in a 2-hour period more than once per month)
19. Tobacco (self-report): Current smokers: any tobacco or e-cigarette/e-nicotine products. Former smokers: Stopped smoking \<10 years at time of screening for those with a ≥20 pack-year smoking history. Stopped smoking \<5 years at time screening for those with a \<20 pack-year smoking history.
20. Recreational drug use (self-report): Self-reported use ≥3 days/week in any form
21. Shift workers (self-report): Night shift work in the last 6 months. Planning night shift work during the study period.
22. Cognitive status (screening): Unable to give consent to participate in and safely complete the protocol, as based on the judgement of the investigators.
23. Psychiatric illness (self-report and screening test): Hospitalization for any psychiatric condition within one year (self-report).
24. Weight change (self-report): Weight change (intentional or not) over the last 2 months of \>5% of body weight. Plan to lose or gain weight during the study
25. Lidocaine or other local anesthetic allergy (self-report): Known allergy to lidocaine or other local anesthetic
26. COVID-19 infection: Individuals who tested positive for COVID-19 but were not hospitalized must be symptom free, at least 14 days (without a negative antigen test) or symptom-free at least 7 days with a negative antigen test on the day of the study visit. A PCR test can be used if antigen tests are not available.
27. Other (clinician judgement): Genetic metabolic disorders that could affect metabolomic results (e.g., phenylketonuria). Any other cardiovascular, pulmonary, orthopedic, neurologic, psychiatric, metabolic, or other conditions that, in the opinion of the local clinician, would preclude participation and successful completion of the protocol. Any other illnesses that, in the opinion of the local clinician, would negatively impact or mitigate participation in and completion of the protocol.

Minimum Eligible Age

65 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes